Welcome to the March 2026 issue of Clinical Thyroidology. I am excited to present this month’s set of interesting reviews on new and impactful research related to thyroid disease. To provide a glimpse, let us do a brief summary of the content!
The issue starts with the topic of medullary thyroid cancer (MTC), befitting of March being the American Thyroid Association’s MTC Awareness Month. In the first, “Less Can Be More, Reviewing the Safety of Lobectomy in Select MTC Cases,” Dr. Matti Gild examines data on differences in multifocality and bilaterality between sporadic and hereditary MTC, highlighting where selective lobectomy for MTC might be viable. In the second, Dr. Elizabeth Cottrill discusses an analysis of how multigene panel testing has transformed the landscape of germline RET pathogenic variant detection, in “RET in the Genomic Era: Moderate Risk Has Become the Majority.”
Keeping with thyroid cancer, but moving to the follicular-derived malignancies, there are three reviews this month. New editorial board member, Dr. Erik Alexander, writes “Reassessing Surgical Extent in N1b Papillary Thyroid Carcinoma,” in which he reviews and comments on how surgical de-escalation might be an appropriate option for some patients who have papillary thyroid carcinoma with lateral lymph node metastasis. Dr. Elias Chuki and Dr. Sinthia Vidal Cañas write “BRAF/MEK Combination Therapy for BRAF V600E Papillary and Anaplastic Thyroid Cancers: Additional Data from Real-World Use,” in which they review retrospective real-world data evaluating dabrafenib plus trametinib in patients with BRAF V600E–positive thyroid cancers. Finally, Dr. Fernanda Vaisman, in “Radioactive Iodine in Intermediate-Risk Differentiated Thyroid Cancer: Bridging Evidence Gaps with Patient Decision Aids,” reviews a study of patients’ concerns and informational needs about radioactive iodine treatment, offering that patient decision aids may help promote more informed, value-concordant care.
Turning to articles focusing elsewhere in thyroid disease, Dr. Natalia Genere and Dr. Sarah Jacob review a meta-analysis showing the potential benefit of adding bile acid sequestrants as adjunctive therapy for difficult-to-control hyperthyroidism, in their review entitled “In a Bind: Role of Bile Acid Sequestrants in Lowering Thyroid Hormone Levels.” The topic of thyroid eye disease is covered by Dr. David Toro-Tobon in “Beyond the Final Dose: The Chronic Glycemic Impact of Teprotumumab,” in which he provides his perspective on the onset and duration of dysglycemia in patients treated with teprotumumab. Finally, Dr. Kaniksha Desai and Faidat A. Ishola cover the topic of hypothyroidism with “Impact of Preexisting Hypothyroidism on Bariatric Surgery Outcomes: Balancing the Risks and Benefits,” which reviews an article demonstrating that preexisting hypothyroidism is associated with increased risks in patients undergoing bariatric surgery from a large health record — based cohort.
It is an issue full of exciting new data and insightful perspectives. All are welcome to join us on social media, where we highlight content from each month’s issue to foster greater dialogue and discussion about the latest clinical thyroid literature and other topics related to thyroid health and disorders. Clinical Thyroidology is found at:
As always, we extend a thank you to the editorial board of Clinical Thyroidology for the Public [CTFP]), led by Dr. Alan Farwell, for providing freely available lay summaries of our Clinical Thyroidology articles each month, which makes this content accessible to patients and the general public who are interested in learning more about recently published studies in the clinical thyroid literature. CTFP can be found online at https://www.thyroid.org/patient-thyroid-information/ct-for-patients.
I welcome your questions, suggestions, or comments at clinicalthyroidology@thyroid.org.
Please visit the Clinical Thyroidology website to see present and past articles, and enjoy reading.
